Schwartz P - Search Results

1

A KRAS-variant in ovarian cancer acts as a genetic marker of cancer risk.

Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. Ratner E, et al. Among authors: schwartz p. Cancer Res. 2010 Aug 15;70(16):6509-15. doi: 10.1158/0008-5472.CAN-10-0689. Epub 2010 Jul 20. Cancer Res. 2010. PMID: 20647319 Free PMC article.

2

Frequent loss of heterozygosity on chromosomes Xp and 13q in human ovarian cancer.

Yang-Feng TL, Li S, Han H, Schwartz PE. Yang-Feng TL, et al. Among authors: schwartz pe. Int J Cancer. 1992 Oct 21;52(4):575-80. doi: 10.1002/ijc.2910520414. Int J Cancer. 1992. PMID: 1399139

3

Allele loss at the retinoblastoma locus in human ovarian cancer.

Li SB, Schwartz PE, Lee WH, Yang-Feng TL. Li SB, et al. Among authors: schwartz pe. J Natl Cancer Inst. 1991 May 1;83(9):637-40. doi: 10.1093/jnci/83.9.637. J Natl Cancer Inst. 1991. PMID: 1673727

4

Early detection of ovarian cancer: background, rationale, and structure of the Yale Early Detection Program.

Schwartz PE, Chambers JT, Taylor KJ, Pellerito J, Hammers L, Cole LA, Yang-Feng TL, Smith P, Mayne ST, Makuch R. Schwartz PE, et al. Yale J Biol Med. 1991 Nov-Dec;64(6):557-71. Yale J Biol Med. 1991. PMID: 1810100 Free PMC article. Review.

5

Early detection of ovarian cancer: preliminary results of the Yale Early Detection Program.

Schwartz PE, Chambers JT, Taylor KJ, Pellerito J, Hammers L, Cole LA, Yang-Feng TL, Smith P, Mayne ST, Makuch R. Schwartz PE, et al. Yale J Biol Med. 1991 Nov-Dec;64(6):573-82. Yale J Biol Med. 1991. PMID: 1810101 Free PMC article.

6

Trisomy 12 and K-ras-2 amplification in human ovarian tumors.

Yang-Feng TL, Li SB, Leung WY, Carcangiu ML, Schwartz PE. Yang-Feng TL, et al. Among authors: schwartz pe. Int J Cancer. 1991 Jul 9;48(5):678-81. doi: 10.1002/ijc.2910480508. Int J Cancer. 1991. PMID: 2071229

7

Development of leukemia after doxorubicin and cisplatin treatment for ovarian cancer.

Chambers SK, Chopyk RL, Chambers JT, Schwartz PE, Duffy TP. Chambers SK, et al. Among authors: schwartz pe. Cancer. 1989 Dec 15;64(12):2459-61. doi: 10.1002/1097-0142(19891215)64:12<2459::aid-cncr2820641210>3.0.co;2-t. Cancer. 1989. PMID: 2819655

8

Tamoxifen in combination with cytotoxic chemotherapy in advanced epithelial ovarian cancer. A prospective randomized trial.

Schwartz PE, Chambers JT, Kohorn EI, Chambers SK, Weitzman H, Voynick IM, MacLusky N, Naftolin F. Schwartz PE, et al. Cancer. 1989 Mar 15;63(6):1074-8. doi: 10.1002/1097-0142(19890315)63:6<1074::aid-cncr2820630606>3.0.co;2-0. Cancer. 1989. PMID: 2917311 Clinical Trial.

9

Urinary human chorionic gonadotropin free beta-subunit and beta-core fragment: a new marker of gynecological cancers.

Cole LA, Wang YX, Elliott M, Latif M, Chambers JT, Chambers SK, Schwartz PE. Cole LA, et al. Among authors: schwartz pe. Cancer Res. 1988 Mar 1;48(5):1356-60. Cancer Res. 1988. PMID: 3342414

10

Prognostic indicators for poor risk epithelial ovarian carcinoma.

Rosman M, Hayden CL, Thiel RP, Chambers JT, Kohorn EI, Chambers SK, Schwartz PE. Rosman M, et al. Among authors: schwartz pe. Cancer. 1994 Aug 15;74(4):1323-8. doi: 10.1002/1097-0142(19940815)74:4<1323::aid-cncr2820740423>3.0.co;2-5. Cancer. 1994. PMID: 8055455

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,823 results

Search Page

Filters